<<<The trouble is whatever you may or may not believe about Teva's chances, it's going to be an overhang on the stock. A few quarters to themselves would go a long way.>>>
No doubt about it, but I can look past a few quarters, because at some point that overhang dissipates and the stock rises as it does and the cash flow starts coming in.
I am just really curious as to how Teva (if it does get approval) is able to garner it, as it does not look to me, if the FDA sticks with its criteria, that there is any reasonable way for Teva to manage to gain approval absent some more "flexibility" by the FDA in evaluating Teva's application. Such flexibility cannot be ruled out. Anyway, that is my conclusion, and probably the basis of Teva's on-going strategy to gain approval despite not having replicated the drug to the degree and extent that MNTA has.
Tinker
Market Data 
Markets 
AI
